Quantification of Globotriaosylsphingosine in Plasma and Urine of Fabry Patients by Stable Isotope Ultraperformance Liquid Chromatography–Tandem Mass Spectrometry | Zendy

Henrik Gold | Zendy; Mina Mirzaian | Zendy; Nick Dekker | Zendy; Maria J. Ferraz | Zendy; Johan Lugtenburg | Zendy; Jeroen D. C. Codée | Zendy; Gijs A. van der Marel | Zendy; Herman S. Overkleeft | Zendy; Gabor E. Linthorst | Zendy; J.E.M. Groener | Zendy; Johannes M. F. G. Aerts | Zendy; Ben J. H. M. Poorthuis | Zendy

Open Access

Quantification of Globotriaosylsphingosine in Plasma and Urine of Fabry Patients by Stable Isotope Ultraperformance Liquid Chromatography–Tandem Mass Spectrometry

Author(s) -

Henrik Gold,

Mina Mirzaian,

Nick Dekker,

Maria J. Ferraz,

Johan Lugtenburg,

Jeroen D. C. Codée,

Gijs A. van der Marel,

Herman S. Overkleeft,

Gabor E. Linthorst,

J.E.M. Groener,

Johannes M. F. G. Aerts,

Ben J. H. M. Poorthuis

Publication year - 2012

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2012.192138

Subject(s) - chromatography , chemistry , urine , tandem mass spectrometry , mass spectrometry , electrospray ionization , liquid chromatography–mass spectrometry , high performance liquid chromatography , metabolite , biochemistry

Biochemical markers that accurately reflect the severity and progression of disease in patients with Fabry disease and their response to treatment are urgently needed. Globotriaosylsphingosine, also called lysoglobotriaosylceramide (lysoGb3), is a promising candidate biomarker.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research